Schedules of Doxorubicin, Cyclophosphamide, Paclitaxel in High-Risk Early-Stage Breast Cancer Compared
the Cancer Therapy Advisor take:
Adjusted weekly dosing for doxorubicin and cyclophosphamide as well as pacilataxel shows similar disease-free survival rates in patients with early-stage breast cancer, according to a recent study published in the Journal of Clinical Oncology.
Comparing continuous with once-every-two-weeks dosing of doxorubicin and cyclophoshamide, as well as once-a-week with six cycles once-every-two-weeks for pacilataxel, researchers found similar disease-free survival rates in any of these regimens in 3,250 patients.
While overall survival was significantly different in each of the four arms, with all treatments that were given once-every-two-weeks being associated with the highest overall survival, this distinction seemed confined only to patients with hormone receptor-negative/human epidermal growth factor receptor 2 (HER2)-negative tumors. The overall survival rate was similar in patients with hormone receptor-positive/HER2-negative or HER2-positive tumors.
Led by George Budd, MD, of the Cleveland Clinic, the study aimed to determine optimal dosage and scheduling of anthracycline and taxane as adjuvant therapy for early-stage breast cancer. They concluded that, upon subset analysis, once-every-two-weeks dosage may be best for patients with hormone receptor-negative/HER2-negative tumors.
Adjusted weekly dosing for doxorubicin and cyclophosphamide as well as pacilataxel shows similar disease-free survival rates.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Larotrectinib: Promising for All TRK-Positive Tumors
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy
- Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- NSCLC: Stratifying Patients With Complex EGFR Mutations